{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 38,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show the evolution of the drug development program.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/17",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Five-stage development process flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03148ed5-46db-47a0-9908-8579df0729bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.8,
        "y": 0.45
      },
      "kind": "list",
      "text": "Phase 2b ATTUNE trial started in July 2021; Topline data expected 1H 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12574548-d6a5-48df-84ce-60c33b760d1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.23,
        "y": 0.45
      },
      "kind": "list",
      "text": "Pharmacometric analysis of Phase 2 PTSD data; Predicted significant efficacy potential with adequate drug exposure achieved",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20a9fd7b-bc70-438f-a2ea-92843c2e62bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Anti-depressant and anti-anxiety trends seen at earlier time points; Safety profile generally well tolerated; Did not meet primary endpoint*; lower than expected exposure of liquid suspension formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "957e7f2d-17b0-49c0-b485-ba0fdb5c2e4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.61,
        "y": 0.45
      },
      "kind": "list",
      "text": "Type C meeting with FDA; FDA granted Fast Track designation in PTSD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdf6208f-f1db-4706-8822-ad96f11d69ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.42,
        "y": 0.45
      },
      "kind": "list",
      "text": "New tablet formulation overcomes food effect of suspension formulation; Achieved exposure target predicted from pharmacometric analysis; Extended IP coverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cebff1d9-cf2a-45e8-b1eb-9a214cb60a57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.13,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Primary endpoint of CAPS-5 total symptom severity score at 12 weeks",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2feb53f8-1112-4e81-a4d3-b00c45f6ef15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210 is Well-Positioned in Post-Traumatic Stress Disorder",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09d7ffe7-f922-4aa7-b4b4-db9f2dbe5cff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "600c2aa8-7609-46bc-a079-1f83e569e8f2",
      "evidence": "Sequential flow of development stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}